Diagnostic Role of F-18 FDG PET/CT in the Follow-up of Patients with Colorectal Cancer: Comparison with Serum CEA, CA 19-9 Levels and Computed Tomography |
Kang, Sung-Min
(Department of Nuclear Medicine, Kyungpook National University Hospital)
Song, Bong-Il (Department of Nuclear Medicine, Kyungpook National University Hospital) Lee, Hong-Je (Department of Nuclear Medicine, Kyungpook National University Hospital) Seo, Ji-Hyoung (Department of Nuclear Medicine, Kyungpook National University Hospital) Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University Hospital) Yoo, Jeong-Soo (Department of Nuclear Medicine, Kyungpook National University Hospital) Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University Hospital) Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University Hospital) Choi, Kyu-Suk (Department of Surgery, Kyungpook National University Hospital) Jun, Soo-Han (Department of Surgery, Kyungpook National University Hospital) |
1 | Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Bur J Cancer 2007;43:1348-60 PUBMED |
2 | Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, et al. FDG-PET in the detection of recurrence in colorectal cancer based on using CEA level. Experience in 72 patients. Gin Positron Imaging 2000;3:170 DOI ScienceOn |
3 | Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976;37:2861-65 DOI ScienceOn |
4 | Wichmann MW, Miller C, Lau-Werner U, Strauss T, Lang RA, Homung HM, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbeck's Arch Surg 2000;385:271-5 DOI ScienceOn |
5 | Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer. comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22 DOI ScienceOn |
6 | Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980;45:2969-74 DOI ScienceOn |
7 | Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-7 DOI PUBMED |
8 | Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20 DOI ScienceOn |
9 | Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201 PUBMED ScienceOn |
10 | Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001;21:1375 PUBMED |
11 | Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-23 DOI ScienceOn |
12 | Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007;5:64 DOI ScienceOn |
13 | Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czemin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89 PUBMED ScienceOn |
14 | Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with resumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130:636-43 DOI ScienceOn |
15 | Staib L, Schimneister H, Reske SN, Beger HG. Is F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5 DOI ScienceOn |
16 | Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen(CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-9 DOI ScienceOn |
17 | Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32 PUBMED ScienceOn |
18 | Kouri M, Pyrhonen S, Kuusela P. Elevated CA 19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78-85 DOI ScienceOn |
19 | Bellomi M, Rizzo S, Travaini LL, Bazzi L, Trifiro G, Zampino MG, et al. Role of multi detector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med 2007;112:681-90 DOI ScienceOn |
20 | Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immumoperoxidase assay. Cancer Res 1982;42:4820-3 PUBMED ScienceOn |
21 | Arularnpalarn T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorecta1 cancer. Eur J Nucl Med 2001;28:1758-65 DOI ScienceOn |
22 | Kim SE, Shong YK, Cho BY, Kim NK, Koh CS, Lee M. Performance characteristic of CA 19-9 radioimmunoassay and clinical significance of serum CA 19-9 assay in patients with malignancy. Korean J Nucl Med 1985;19:119-26 과학기술학회마을 |
23 | Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67 DOI ScienceOn |
24 | Kelly CJ, Daly JM Colorectal cancer. Principles of postoperative follow-up. Cancer 1992;70(Suppl 5):1397-408 DOI ScienceOn |
25 | Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995;130:1062-7 DOI PUBMED |
26 | Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001;28:1758-65 DOI ScienceOn |
27 | Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11 DOI ScienceOn |
28 | Del Villano BC, Zurawski VR Jr. The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker. Lab Res Methods Biol Med 1983;8:269-82 PUBMED |
29 | Turk PS, Wanebo HJ. Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer 1993;71(Suppl 12):4267-77 DOI ScienceOn |